Home

Biotech

Broadband

B2B Internet

Europe 2001

Internet

Internet 
Architecture

Internet 
Infrastructure

Market 2000+

Oil Services

Pharmaceutical

Regional Bank

Retail

Semiconductor

Software

Telecom

Utilities

Wireless
Biogen Idec Inc (NASDAQ GS:BIIB)7/28/2010
most recent headlinesmore headlines:       
MONDAY, JULY 26, 2010
10:00 AMCritical Insider Trade News for QLogic, Momenta Pharmaceuticals, Skyworks, T. Rowe Price, E*TRADE Financial, & Biogen Idec; Reported by Insiderslab.com - PR Newswire
WEDNESDAY, JULY 21, 2010
8:00 AMCimzia Matches Simponi on Key Performance Metrics in the Treatment of RA and Actemra Uptake Continues, Despite Need for Lab Monitoring - PR Newswire
TUESDAY, JULY 20, 2010
7:15 AMBiogen Idec Reports Second Quarter 2010 Results - BusinessWire
THURSDAY, JULY 15, 2010
8:00 AMSurveyed Neurologists' Awareness of Merck Serono/EMD Serono's Oral Cladribine is Double that of Novartis/Mitsubishi Tanabe's FTY-720 (Gilenia) - PR Newswire
MONDAY, JULY 12, 2010
8:00 AMThe Launch of Eight Novel Disease-Modifying Therapies, Including the First Oral Agents Approved for the Indication, Will Drive Modest Growth in the Multiple Sclerosis Drug Market Through 2019 - PR Newswire
5:25 AMSwedish Orphan Biovitrum, Biogen Idec to move haemophilia A drug to registrational trial - M2
2:30 AMBiogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Hemophilia B Therapy at the World Federation of Hemophilia Congress - BusinessWire
FRIDAY, JULY 09, 2010
9:39 AMBiogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial - BusinessWire
9:30 AMBiogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia a Therapy into a Registrational Trial - BusinessWire
WEDNESDAY, JUNE 30, 2010
4:14 PMExelixis Announces Appointment of New CEO - BusinessWire


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

HOLDRS Defined |  HOLDRS Outstanding  |  FAQ  |  Proxies by email  |  Investment Strategies
Spin-Offs & Changes  |  Current Trading  |  Download a Prospectus  |  Site Map

Merrill Lynch, Pierce, Fenner & Smith Incorporated is a registered broker-dealer and a wholly-owned subsidiary of Bank of America Corporation.
Securities Products: Are Not FDIC Insured • Are Not Bank Guaranteed • May Lose Value.

The information in this Internet site is directed at, and is intended for distribution to, and for use by, persons in the U.S. only, and is not intended for distribution to or use by any person in any other jurisdiction. Merrill Lynch does not warrant the accuracy or completeness of any price, tax, cost basis, or other information on this site, or any investment, tax or other benefits associated with HOLDRS.

The information on HOLDRSSM contained in this Internet site is solely for informational purposes and does not constitute either an offer to sell or the solicitation of an offer to buy HOLDRS. This information on HOLDRS is not, and is not intended to be, a complete discussion of all material information you should know about HOLDRS. If you are considering whether to purchase a HOLDRS security, you should carefully read the relevant prospectus prior to making a purchase. You should not rely on the information contained in this Internet site. Please view Terms of Use and Legal Notices for additional important legal information and the terms and conditions governing your use of this site.

U.S. Patent Pending.
HOLDRS and HOLding Company Depositary ReceiptS are service marks of Merrill Lynch & Co., Inc.

© Copyright 2000, Merrill Lynch, Pierce, Fenner & Smith Incorporated. Member, Securities Investor Protection Corporation (SIPC). All rights reserved.